The Drugs Controller General of India has issued an alert for batch KE25012 of the Abhayrab rabies vaccine due to potency failures and packaging inconsistencies. Produced by Indian Immunologicals Limited, this is the company's second quality concern in less than two years. The alert highlights potential supply chain risks for the manufacturer, which holds approximately 40% of the domestic rabies vaccine market.
The Drugs Controller General of India (DCGI) has issued a safety alert regarding batch KE25012 of the Abhayrab rabies vaccine. This move follows testing by the Central Drugs Laboratory in Kasauli, which found that samples from the batch failed to meet critical potency requirements. Consequently, the regulator has officially classified the batch as 'not of standard quality' and 'misbranded.'
The investigation revealed physical differences between the batch in question and the authorized reference samples maintained by the manufacturer, Indian Immunologicals Limited (IIL). Authorities identified inconsistencies in labeling, artwork, and QR code verification, alongside variations in cap colors and packaging text. Due to these discrepancies, the regulator has categorized the product as potentially spurious, signaling serious concerns regarding the integrity of the distribution chain.
This incident is notable because it is the second time in under two years that IIL has faced a public quality or security concern regarding this specific vaccine. In January 2025, counterfeit batches of the same product triggered international alerts, leading to warnings from health authorities in the United States, Britain, and Australia. For a company that serves as a major supplier for life-saving prophylaxis, repeated issues with product integrity often lead to increased regulatory scrutiny and stricter compliance audits.
Financially, Indian Immunologicals Limited remains a significant entity in the pharmaceutical sector. For the financial year 2026, the company reported a record turnover of ₹1,586 crore, underpinned by strong operational efficiency and a solid balance sheet. CRISIL Ratings has previously reaffirmed the company’s credit rating at 'CRISIL AA+/Stable,' reflecting its strong capital structure and overall market position. Despite these robust financial metrics, the latest regulatory finding introduces operational risk, particularly as the company commands a dominant 40% share of India's domestic rabies vaccine market.
Rabies remains a significant public health challenge in India, with thousands of fatalities reported annually. Because Abhayrab is a primary defense for both pre- and post-exposure treatment, any disruption in supply or questions about drug efficacy carry substantial public health implications. The company’s ability to maintain trust with institutional buyers and government tender authorities will likely depend on how effectively it addresses these quality control and supply chain gaps.
Investors and stakeholders in the pharmaceutical sector will likely monitor further communications from the DCGI and the company. Key updates to track include the scale of the product recall, the specific findings of the company's internal investigation into the supply chain discrepancies, and whether the regulator imposes stricter manufacturing oversight or limitations on future tender participation.